Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRoquefort Thera Regulatory News (ROQ)

  • There is currently no data for ROQ

Corporate Update

19 Jul 2021 07:00

RNS Number : 5009F
Roquefort Investments PLC
19 July 2021
 

19 July 2021

 

roquefort investments PLC

("Roquefort Investments" or the "Company")‎

 

Corporate Update

 

Roquefort Investments plc, an investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, provides the following corporate update.

 

Further to the admission of the Company's shares to the Official List by way of a standard listing and to trading on the London Stock Exchange in March 2021, the Company has been progressing the formal screening of various compelling opportunities in line with its stated objective of acquiring a biotechnology business that is in the "research" or "pre-clinical development" stage in the medical sector. Whilst the Company is at an early stage in such process, the Board is encouraged by the initial due diligence it has initiated.

The Company has not been negatively impacted by the ongoing COVID-19 pandemic and believes it will ultimately benefit from the increased market focus on the medical biotechnology industry in the current environment.

Roquefort Investment's business model is well tailored to the current climate in terms of maintaining low overheads to preserve cash, seeking early-stage established businesses in the medical biotechnology industry enabling a cost-effective entry point to compelling opportunities, and utilising the commercial and technical capabilities of its management team to progress opportunities internally.

 

Stephen West, Chairman of Roquefort Investments, commented:

"The current environment has undoubtedly led to more opportunities in the exciting biotechnology sector coming to our attention, which we have now high-graded in order to focus on the most compelling. These high-graded opportunities are fully consistent with our strategy and we are most encouraged by the progress we are making with our initial due diligence discussions. We hope to provide a more detailed update in due course as these discussions progress further and we have narrowed down our selection to an appropriate target."

Enquiries:

Roquefort Investments plc

Stephen West (Chairman)

+44 (0)20 3290 9339

Optiva Securities Limited (Broker)

Christian Dennis

+44 (0)20 3411 1881

 

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

 

 

About Roquefort Investments

Roquefort Investments was formed as an investment company to acquire businesses focused on early-stage opportunities in the medical biotechnology sector with the aim of generating optimal returns for both the target businesses and our shareholders. It is envisaged that such acquisition or acquisitions will trigger a reverse takeover in accordance with the listing rules.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBGGDRRDBDGBL
Date   Source Headline
30th Jun 20224:38 pmRNSDirector/PDMR Shareholding
30th Jun 202210:30 amRNSResult of AGM
23rd Jun 20227:00 amRNSUpdate on Acquisition of Oncogeni and Placing
22nd Jun 20224:42 pmRNSIssue of Warrants
22nd Jun 202210:32 amRNSInvestor Presentation
22nd Jun 20229:05 amRNSSecond Price Monitoring Extn
22nd Jun 20229:00 amRNSPrice Monitoring Extension
22nd Jun 20227:00 amRNSProposed Acquisition of Oncogeni Limited & Placing
13th Jun 20227:00 amRNSNotice of AGM - Correction
7th Jun 20227:00 amRNSPre-clinical Update
7th Jun 20227:00 amRNSNotice of AGM
11th May 20227:00 amRNSAnnual Report & Financial Statements
20th Apr 20227:00 amRNSNon-Executive Director Appointment
5th Apr 20227:00 amRNSBoard Appointment
22nd Mar 20228:08 amRNSHolding(s) in Company
21st Mar 20229:34 amRNSInvestor Presentation
21st Mar 20227:00 amRNSPatent Filed – New Drug Class Targeting Midkine
8th Mar 20227:54 amRNSHolding(s) in Company
14th Feb 20227:00 amRNSAppointment of Strategic & Scientific Advisor
8th Feb 202211:35 amRNSHolding(s) in Company
28th Jan 20227:00 amRNSHolding(s) in Company
19th Jan 202212:56 pmRNSDirector/PDMR Shareholding
19th Jan 20228:39 amRNSHolding(s) in Company
18th Jan 20222:00 pmRNSPrice Monitoring Extension
18th Jan 202211:51 amRNSHolding(s) in Company
17th Jan 20227:00 amRNSHolding(s) in Company
17th Jan 20227:00 amRNSPre-clinical Update
10th Jan 20228:00 amRNSPublication of New Research
31st Dec 20217:00 amRNSChange of Company Name
22nd Dec 20217:00 amRNSHolding(s) in Company
21st Dec 20219:06 amRNSSecond Price Monitoring Extn
21st Dec 20219:00 amRNSPrice Monitoring Extension
21st Dec 20217:00 amRNSAcquisition Completion, Admission & Voting Rights
16th Dec 20214:24 pmRNSPublication of Prospectus
13th Dec 20211:19 pmRNSResults of General Meeting
22nd Nov 20217:00 amRNSConditional Placing to Raise £3 Million
19th Nov 20217:00 amRNSCircular and Notice of General Meeting
18th Nov 20217:00 amRNSProposed Acquisition of Lyramid Pty Limited
12th Nov 20217:33 amRNSUpdate on Acquisition of Lyramid Limited
29th Oct 20212:01 pmRNSInterim Results to 30 June 2021
20th Oct 20217:00 amRNSBoard Changes
29th Sep 20217:34 amRNSReverse Takeover & Suspension of Trading
29th Sep 20217:30 amRNSSuspension - Roquefort Investments Plc
26th Aug 202112:42 pmRNSHolding(s) in Company
25th Aug 202111:06 amRNSSecond Price Monitoring Extn
25th Aug 202111:00 amRNSPrice Monitoring Extension
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20212:44 pmRNSHolding(s) in Company
24th Aug 20212:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.